Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

First Author:  Hyon-Xhi Tan 

Journal/preprint name: bioRxiv 

Tags: Vaccine 

Summary  

In this preprint, the authors present their data comparing the efficacy and immunogenicity of both homologous and heterologous prime-boost vaccination of mice and macaques with either a viral spike (S) or a RBD subunit vaccine.  S vaccines elicited superior immunogenicity in mice and comparable responses to RBD vaccination in macaques.   Study highlights the potential of using recombinant spike protein as a vaccine candidate and highlights key differences in vaccine responses between mice and macaques. 

Research Highlights  

  1. In mice, serum antibody titres, and GC B Cell and TFH cell responses are markedly improved with a single immunization of S rather than RBD 

  1. Homologous (RBD-RBD or S-S) or heterologous (RBD-S or S-RBD) prime boost vaccination of mice, elicited poor immunogenic responses if S was not included in the vaccination strategy.  

  1. Homologous (RBD-RBD or S-S) and heterologous (S-RBD) vaccination of macaqueselicited comparable immunogenic responses with all vaccine strategies utilized. 

  1. A comparison of serum and neutralizing Ab titres revealed that responses to vaccination in mice far exceed those observed in convalescent Covid patients*see limitation below. 

Impact for COVID-19 research:  

  • Provides evidence that the immunological response to vaccination can be improved by including the spike protein alongside the RBD. 

  • Demonstrates the differences in the immunological response between mouse and non-human primates to the same vaccine-strategy, with particular reference to the differing VH gene usage and how this impacts on the generation of B cell responses post vaccination.  

Methodologies: 

  • Study Type: In vivo (mouse and NHP). 

  • Important cell lines/viral models used: Vaccine study 

  • Key Techniques: Flow cytometric analysis of S and RBD-specific B cells and TFH cells, BCR sequencing, ACE2-RBD inhibition ELISA.  

Limitations: 

  • As with all macaques studies the numbers are small, however, it is difficult to draw firm conclusions with a N of 2.  Furthermore, the presentation of data in Figure 3 is particularly difficult to interpret for some of the panels. 

  • There are differences between the vaccine approaches used in the mice and macaques and this is not discussed by the authors.  A vaccination dose-response, at least in mice should have been considered.  

  • In the macaque model, the RBD-S prime-boost vaccine has not been studied and the authors provide no explanation as to why. 

  • The patients recruited for the convalescent and B Cell studies, are mainly mild infections, but do include some severe individuals, would have been useful to highlight the severe patients in Figure 4.